Galecto, Inc. (GLTO)
NASDAQ: GLTO · Real-Time Price · USD
3.390
+0.185 (5.77%)
Aug 4, 2025, 11:46 AM - Market open

Company Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases.

The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications.

Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Galecto, Inc.
Galecto logo
CountryDenmark
Founded2011
IPO DateOct 29, 2020
IndustryBiotechnology
SectorHealthcare
Employees5
CEOHans Schambye

Contact Details

Address:
Ole Maaloes Vej 3, Copenhagen N
Copenhagen, 2200
Denmark
Phone45 70 70 52 10
Websitegalecto.com

Stock Details

Ticker SymbolGLTO
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code0001800315
CUSIP Number36322Q107
ISIN NumberUS36322Q2066
Employer ID37-1957007
SIC Code2834

Key Executives

NamePosition
Dr. Hans T. Schambye M.D., Ph.D.Co-Founder, President, Chief Executive Officer and Director
Lori C. FirmaniInterim Chief Financial Officer
Garrett Winslow Esq.Senior Vice President, General Counsel and Corporate Secretary
Ulf J. Nilsson Ph.D.Co-Founder
Dr. Hakon Leffler M.D., Ph.D.Co-Founder
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.Co-Founder
Matthew KronmillerExecutive Vice President of Strategy and Chief Business Officer

Latest SEC Filings

DateTypeTitle
Jun 20, 20258-KCurrent Report
May 8, 202510-QQuarterly Report
Apr 30, 2025ARSFiling
Apr 30, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 30, 2025DEF 14AOther definitive proxy statements
Apr 17, 2025PRE 14AOther preliminary proxy statements
Mar 19, 2025S-8Securities to be offered to employees in employee benefit plans
Mar 19, 202510-KAnnual Report
Jan 16, 2025SCHEDULE 13D/AFiling
Nov 7, 2024SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals